IL-32 Levels in Patients With Chronic Periodontitis

Overview

Interleukin-32 (IL-32) is a recently described cytokine that is a strong inducer of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α. A previous report have reported that Porphyromonas gingivalis-derived LPS significantly up-regulated IL-32 expression compared with the unstimulated cells in monocytes (THP-1 cells). They suggested that IL-32 may contribute to the pathogenesis of periodontal disease. In the present study the investigators hypothesized that IL-32 levels may increase in the gingival crevicular fluid (GCF) and saliva of patients with chronic periodontitis compared with healthy controls and these levels may decrease together with treatment.

Full Title of Study: “IL-32 Levels in Gingival Crevicular Fluid and Saliva of Patients With Chronic Periodontitis After Periodontal Treatment.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Diagnostic
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: May 2015

Detailed Description

The purpose of this study was to investigate IL-32 levels in the GCF and saliva of patients with chronic periodontitis and to evaluate changes after nonsurgical periodontal therapy. Twenty-seven CP and 27 periodontally healthy controls were enrolled in this study. Periodontitis patients received nonsurgical periodontal treatment. GCF and saliva sampling and clinical periodontal parameters were assessed before and a month after treatment. IL-32, IL-10 and TNF-α levels in GCF and saliva were measured by enzyme-linked immunosorbent assay. Unstimulated salivary samples were collected using standard techniques. About 2 mL whole saliva was collected in disposable tubes and centrifuged immediately to remove cell debris (10,000 g x 10 minutes). The supernatants (50µL each) were stored at -40C until analyzed. GCF samples were collected from a mesio-buccal and disto-palatal site on each tooth. In the CP group, the samples were obtained from patients at areas with ≥5 mm CAL, ≥6 mm PD and ≥30% bone loss. In the healthy group, GCF samples were collected from teeth exhibiting PD<3 mm without CAL and BOP. The area was isolated with cotton rolls, saliva contamination elimination was ensured, and it was slightly air dried. GCF was sampled with paper strips. Paper strips were placed into the crevice until mild resistance was felt (intracrevicular method) and left in the position for 30 seconds. Strips contaminated with blood or saliva were discarded. Each sampled strip was placed into a 400µl eppendorf centrifuge tube and stored at -40C until analyzed.

Interventions

  • Other: nonsurgical periodontal treatment
    • Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
  • Other: Gingival crevicular fluid and saliva collection
    • GCF collection with filter paper (Periopaper) using the intracrevicular method. Patients’ mouths were rinsed with distilled water, and unstimulated salivary samples were collected by patients expectorating into disposable tubes.

Arms, Groups and Cohorts

  • Active Comparator: chronic periodontitis patients
    • gingival crevicular fluid and saliva collecion were taken before and after nonsurgical periodontal treatment
  • Placebo Comparator: periodontally healthy controls
    • gingival crevicular fluid and saliva collection were taken at baseline after oral hygiene instructions

Clinical Trial Outcome Measures

Primary Measures

  • Biochemical parameters (IL-32, IL-10 and THF-alpha)
    • Time Frame: Baseline and 1 month after treatment
    • The changes in levels of IL-32 after periodontal treatment determined by ELISA. The changes in levels of IL-32 were analyzed to determine diagnostic and prognostic potential as a biomarker of periodontitis.

Secondary Measures

  • Probing pocket depth
    • Time Frame: Baseline and 1 month after treatment
    • The changes in probing pocket depth after periodontal treatment.Probing pocket depth was measured for determining severity of disease and clinic outcome.
  • Probing pocket depth and clinical attachment level
    • Time Frame: Baseline and 1 month after treatment
    • The changes in clinical attachment level after periodontal treatment. The probing depth and the distance from the gingival margin to the cemento-enamel junction are used to measurement of clinical attachment level. Clinical attachment level was measured for determining severity of disease and clinic outcome.
  • Gingival index
    • Time Frame: Baseline and 1 month after treatment
    • The changes in gingival index after periodontal treatment. Gingival index was recorded for classifying and evaluating (coronally) gingival inflammation.
  • Plaque index
    • Time Frame: Baseline and 1 month after treatment
    • The changes in plaque index after periodontal treatment. Plaque index was recorded for determining and classifying oral hygiene status.
  • Bleeding on probing
    • Time Frame: Baseline and 1 month after treatment
    • The changes in bleeding on probing after periodontal treatment. Bleeding on probing was recorded for classifying and evaluating (apically) gingival inflammation.

Participating in This Clinical Trial

Inclusion Criteria

  • all subjects in the study were possess of at least 20 teeth excluding third molars. Exclusion Criteria:

  • agressive periodontitis, – periapical pathologies, – excessive forces including mechanical forces caused by orthodontic forces and occlusal forces; – presence of systemic diseases; – administration of non-steroidal and anti-inflammatory drugs or antibiotic therapies within the previous 6 months; – need for antibiotic prophylaxis for dental treatment and having received non-surgical periodontal treatment within the past 6 months or surgical periodontal treatment within the past 12 months; – allergy or sensitivity to any drug, – pregnancy, – lactation, and – current and former use of tobacco.

Gender Eligibility: All

Minimum Age: 35 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Bulent Ecevit University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Figen ÖNGÖZ DEDE, Bülent Ecevit University Faculty of Dentistry – Bulent Ecevit University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.